Oxford finds COVID-19 shot 76% effective for 3 months after single dose
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
LONDON (Reuters) - The Pfizer-BioNTech COVID-19 vaccine may be less able to protect against infection with a South African variant of the virus that has a worrying mutation, according to results of a British study released on Tuesday.
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in that country and South Africa.
Submitted by mike kraft on
England will remain in a national lockdown until at least early March when schools are set to reopen, Boris Johnson has said, and travellers into Britain from high-risk nations will now have to quarantine inside hotels.
Submitted by mike kraft on
LONDON — The vaccine wars have come to Europe.
For months now, wealthy countries have been clearing the world’s shelves of coronavirus vaccines, leaving poorer nations with little hope of exiting the pandemic in 2021. But a fresh skirmish this week has pitted the rich against the rich — Britain versus the European Union — in the scramble for vials, opening a new and unabashedly nationalist competition that could poison relations and set back collective efforts to end the pandemic.